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Traumatic injury is a common problem, with over five million worldwide deaths from trauma per year. An
estimated 10 to 20% of these deaths are potentially preventable with better control of bleeding. Damage control
resuscitation involves early delivery of plasma and platelets as a primary resuscitation approach to minimize
trauma-induced coagulopathy. Plasma, red blood cell and platelet ratios of 1:1:1 appear to be the best substitution
for fresh whole blood; however, the current literature consists only of survivor bias-prone observational studies.
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Key points
 Damage control resuscitation is now the
predominant focus upon arrival in hospital.
Crystalloid delivery should be minimized, as it can
be associated with harm.
 Trauma-induced coagulopathy is a common
problem caused by dilution and consumption of
clotting factors, hypothermia and acidosis. Evidence
suggests it can be decreased by early delivery of
blood products.
 The best resuscitation appears to be with whole
blood rather than component therapy. Can 1:1:1
ever be an adequate substitute for fresh whole
blood, or should blood banks consider a return to
using whole blood?
 The use of Factor VII is controversial and is usually
no longer necessary with early delivery of blood
products. It was probably mainly used to treat an
iatrogenic coagulopathy. Tranexamic acid should be
considered and is significantly cheaper.
 Giving unnecessary plasma and platelets should be
discouraged in order to reduce the risk of
transfusion-related acute lung injury. Point of careCorrespondence: timothy.miller2@duke.edu
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reproduction in any medium, provided the origincoagulation tests may aid decision-making and
reduce unnecessary transfusions.
 Massive transfusion protocols improve
communication and delivery of blood products to
the patient. They enable clinicians to give fresh
plasma up front, rather than giving red blood cells
initially and plasma later.Review
The problem of traumatic injury
Traumatic injury is the leading cause of death between
the ages of 1 and 40 [1]. An estimated five million
people die per year worldwide from traumatic injuries
[2]. It has been estimated that 10 to 20% of these deaths
are potentially preventable [3]. The biggest cause of
preventable death is early hemorrhage within the first
6 hours after incurring an injury [1], which has led trauma
teams to investigate whether a change in practice could
help reduce early mortality after severe trauma.
It is important to note that only 25% of trauma patients
actually receive a blood transfusion, with just 2 to 3% of
civilian traumas and 7 to 8% of military trauma patients
receiving a massive transfusion (MT) [4]. The definition
of a MT varies within the literature. The most commonly
used definition is a transfusion of greater than 10 units of
packed red blood cells (RBCs) within 24 hours [5].
Patients receiving a MT therefore form a small pro-
portion of the overall trauma burden. The majority of
trauma patients do not need blood products or the uses an Open Access article distributed under the terms of the Creative
mons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
al work is properly cited.
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the most severely injured patients requiring MT that are
at risk of early hemorrhagic death. These patients have a
mortality ranging from 40 to 70% at leading trauma
centers [2] and may benefit from the early use of blood
products and damage control resuscitation (DCR) as
described in this review.
The history of transfusion
The major changes in blood transfusion practice over
the last 100 years have largely occurred based on the ex-
perience of military physicians during the major conflicts
of the 20th century. The first use of preserved blood for
transfusion was carried in 1917 by Captain Oswald H.
Robertson from the United States Army Medical Officer
Reserves Corps for the British First Army during the Battle
of Cambrai in the First World War and was remarkably
successful [6,7]. He transfused O-negative blood, which had
been stored for 14 days and brought to the front line. This
led to the use of transfusion in the final year of the war, in
combination with saline and colloids [8]. By the time of the
Second World War, albumin and lyophilized (freeze-dried)
plasma were being used in combination with whole blood
to achieve a balanced resuscitation [9] - not dis-similar to
practices that are being advocated today. Since the Second
World War we have almost gone full circle, which means
that first practice changed for the worse.
Transfusion methods altered dramatically around the
time of the Vietnam War in the 1970s, when practice
changed from using whole blood to component therapy.
This was primarily due to the need for better resource
utilization, and to reduce infectious disease transmission.
This change in practice was accepted without support
from randomized controlled trials or large retrospective
studies in MT, and as a rule people did not adapt well to
using component therapy. There was confusion as to how
to use component therapy for MT, with underuse of
clotting products being the norm. As a result, inadvertent
hemodilution became routine as a part of MT in the 1970s
and 1980s. Failure to control bleeding led to a vicious cycle
of problems that became known as the ‘lethal triad’ of
trauma: coagulopathy, hypothermia and acidosis.
At that time, giving a significant amount of crystalloid
upfront on admission was common practice, which created
various problems including abdominal compartment
syndrome, acute respiratory distress syndrome (ARDS) and
multiple organ failure [10]. Products other than crystalloid
were only considered much later in the treatment process
after laboratory results had been analyzed or problems had
already begun to develop.
Finally, in the late 1990s clinicians started realizing the
deleterious effects of excess crystalloid [11,12]. This led to
a return to the balanced resuscitation that was reminiscent
of that described in the Second World War.Trauma-induced coagulopathy
Trauma-induced coagulopathy is an important predictor
of blood utilization and trauma-related mortality [13].
It is mainly an iatrogenic or secondary coagulopathy, a
condition in which various elements are thought to play a
role, including ongoing dilution and consumption of
clotting factors from crystalloid and RBCs, acidosis and
hypothermia [12].
Recently, it has been proposed that this secondary
coagulopathy is preceded by an early trauma-induced
coagulopathy (ETIC). ETIC is defined as prolonged PT
upon admission and has been described as a separate
phenomenon to trauma-induced coagulopathy in that it
is an early and primary event. The cause of ETIC is un-
known although several theories have been proposed.
One theory attempting to explain the cause of ETIC is
that the actual injury causes release of tissue factor,
which consequently causes thrombin and fibrin generation
and utilization, and disseminated intravascular coagulation
[14]. Another theory suggests that the hypoperfusion and
ischemia known to be associated with trauma can cause
release of activated protein C, which leads to consump-
tion of plasminogen activator inhibitor (PAI-1), inhib-
ition of the clotting cascade, systemic anti-coagulation
and hyperfibrinolysis [15].
A recent case-control study by Shaz looking only at
patients with ETIC found no difference between the
cases and the controls in thrombin or fibrin generation,
and no difference in the amount of fibrinolysis [16]. It
was found that patients with ETIC had been given
more crystalloid in the pre-hospital admission phase;
therefore they concluded ETIC may not be a unique
pathophysiologic response but rather a secondary trauma-
induced coagulopathy that occurs before a patient reaches
the hospital.
What is clear is that the coagulopathy of trauma
(whether it is called ETIC, trauma-induced coagulopathy or
alternate terms such early coagulopathy of trauma and
acute coagulopathy of trauma shock) is associated with an
increase risk of bleeding and mortality [16]. Therefore care
must be taken to decrease trauma-induced coagulopathy
where possible. This can be achieved by reducing the
amount of crystalloids given initially. Ley et al. analyzed
prospectively collected data from 3,137 trauma patients at a
level-1 trauma center between 2000 and 2008 in an attempt
to identify the factors responsible for increased mortality
after trauma. After multivariate logistic regression analysis
the resulting factors included many that were expected
including injury severity scores greater than 16, a Glasgow
coma scale (GCS) of less than 8, hypotension and an
age greater than 80. Another major factor was having
received IV crystalloid of greater than 1.5 liters in the
emergency department, which was an independent
risk factor for mortality in both elderly (>70 years old)
Miller Perioperative Medicine 2013, 2:13 Page 3 of 7
http://www.perioperativemedicinejournal.com/content/2/1/13(OR 2.89 (1.13 to 7.41, P = 0.027) and non-elderly patients
({OR 2.09 (1.31-3.33), P = 0.002). High-volume (>3 liter)
crystalloid resuscitations were associated with particularly
high mortality in elderly patients (OR 8.61 (1.55 to 47.75),
P = 0.014).
A recent study in South Africa, looking at the use of
either colloid or crystalloid in early trauma patients,
showed that superior initial resuscitation using colloid
instead of crystalloid resulted in decreased lactate levels
and less renal injury after penetrating trauma [17]. The
superior intravascular retention with the colloid enabled
better tissue resuscitation. These results are supported
by a recent observational study [18].
Damage control resuscitation
The concept of damage control resuscitation (DCR) was
proposed in the mid 2000s as an alternative resuscitation
approach to hemorrhagic shock. Damage control resuscita-
tion involves:
1. Rapid control of surgical bleeding
2. Early and increased use of red blood cells, plasma
and platelets in a 1:1:1 ratio
3. Limitation of excessive crystalloid use
4. Prevention and treatment of hypothermia,
hypocalcemia and acidosis
5. Hypotensive resuscitation strategies
The first major study looking at damage control resusci-
tation was carried out by Borgman and colleagues at the
US combat hospital in Iraq [19]. This retrospective study
looked at 252 patients who had been given a MT, and
found a pronounced difference in mortality between
patients who had low, medium or high plasma to red
blood cell ratios; the higher the plasma ratio in the blood,
the lower the risk of mortality. This was achieved by
primarily reducing early (<4 hours from admission)
death from hemorrhage. Other studies in military trauma
have also shown a mortality benefit from high plasma:
RBC ratios [20-22].
Holcomb described similar results in 466 MT civilian
patients transported to 16 Level 1 trauma centers in the
United States [23]. Thirty-day survival was significantly
increased in patients with high plasma:RBC ratios (>1:2)
compared to those with low plasma:RBC ratios (<1:2). They
also showed that a combination of high plasma and high
platelet ratios (>1:2) increased 6-hour, 24-hour and 30-day
survival. Since studies looking at blood product ratios are
trying to prevent death from uncontrolled hemorrhage
it is important to measure mortality at 6 hours. Later
end-points are also relevant as increased exposure to
plasma could be reflected in an increased incidence of late
deaths from transfusion related lung injury (TRALI), ARDS
and multi-organ failure. Sperry and colleagues found asignificant reduction in early (24 hour) mortality with
plasma:RBC ratio >1:1.5 in MT, but a higher risk of
ARDS [24].
It is important to note that currently all studies
looking at blood product ratios in both civilian and mili-
tary trauma are observational studies. They are therefore
prone to survivor bias due to the fact that many deaths
occur early in the hospital course when the patients are
more likely to be in the low ratio group [25]. A further
confounding factor is that patients who have more severe
injuries and receive relatively higher quantities of RBCs
are both more likely to receive a lower plasma:RBC ratio
and are more likely to die [26].
What about platelets?
After plasma:RBC ratios had been identified as an import-
ant component of a MT, Perkins and colleagues focused
on platelet ratios in military trauma [27]. The high ratio
group received approximately 1:1 platelets to RBCs, and
had improved 24-hour and 30-day survival rates com-
pared to other groups. This study however aptly illustrates
the problems of survivor bias; the median time to death in
the low platelet group was 2.3 hours, whereas the overall
median time to administering the first units of platelets
was 2.5 hours.
Higher platelet:RBC ratios (>1:2) have also been shown
to improve 24-hour and 30-day survival after MT second-
ary to civilian trauma [23,28,29]. The current US military
resuscitation approach is to use 1:1:1 resuscitation for all
combat casualties expected to receive a MT [2].
What about fibrinogen?
One unit of fresh whole blood contains 1000 mg of
fibrinogen, therefore losing a unit of blood also dispels
1000 mg of fibrinogen. It is common practice to replace
this loss with one unit of RBCs and one unit of fresh
frozen plasma (FFP), which restores approximately 500 mg
of fibrinogen, and so in a MT it is necessary to add more
fibrinogen at a later stage. This is usually done with cryo-
precipitate, which is derived from the precipitate fraction
of cold-thawed human plasma. For example, 10 units of
cryoprecipitate given in a MT will contain 2.5 g of cryopre-
cipitate, thus compensating for the fibrinogen deficit.
Stinger et al. showed that a high fibrinogen:RBC ratio
(>0.2 g of fibrinogen:RBC) was independently associated
with survival to discharge after military trauma (survival
76% versus 48%, P <0.001) [20]. As 1 unit of cryoprecipitate
contains 0.25 g of fibrinogen that ratio can be achieved by
transfusing cryoprecipitate:RBC in a 1:1 ratio. In practice
this is usually done by transfusing one 10-unit bag of
cryoprecipitate for every 10 units of red cells transfused.
A cryoprecipitate:RBC ratio of 1:1 has also been shown
to reduce 24-hour and 30-day mortality after MT in
civilian trauma [28].
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Spinella et al. compared the use of warm fresh whole
blood (WFWB) to component therapy from a transfusion
database at the US Army Institute of Surgical Research
[21]. They looked at all combat casualty patients from both
Iraq and Afghanistan who were transfused with >1 unit of
RBCs. The patients who received WFWB got on average
only 30% WFWB and 70% component therapy, however
their survival rate was far better than patients who had
received component therapy alone.
The results of this study suggest that there must be a
significant advantage to using WFWB over component
therapy. Patients receiving WFWB are given 500 ml of
warm blood with no storage deficits and good hematocrit
levels. WFWB also contains the full amount of platelets,
clotting factors and fibrinogen and is therefore healthier
and more beneficial to the patient. Even ‘best’ practice
component therapy in a 1:1:1 ratio of platelets, plasma
and RBCs does not contain comparable levels of platelets,
clotting factors, or fibrinogen [30]. When components are
reconstituted after the addition of anti-coagulants and
additive solutions a cold, dilute product is produced.
Storage lesions also occur in the stored blood products
leading to decreased RBC deformability and reduced
platelet function [30,31]. Therefore even best practice
component therapy using the 1:1:1 formula is not as
effective as fresh whole blood.
Other drug therapies
The use of recombinant Factor VII (rFVII) in trauma is
controversial, and has decreased in recent years. It may
be that rFVII was used to treat an iatrogenic resuscita-
tion injury caused by overuse of crystalloid and RBCs.
As a practice has developed of giving more plasma and
platelets upfront, rFVII has fallen out of use and is
frequently no longer necessary in trauma surgery. One
study investigating the use of Factor VII within a major
trauma center found no correlation between the use of
the drug and outcome benefit; its use seemed to merely
prolong death rather than prevent it [32]. Other trials
in have also shown a lack of benefit [33] and evidence
of harm [34].
Tranexamic acid has been suggested as a cheaper al-
ternative to Factor VII. The Crash-2 trial randomized
over 20,000 trauma patients to either tranexamic acid
or control. Tranexamic acid significantly reduced the
risk of death (OR 0.91 (0.85 to 0.97), P = 0.0035) and
death from hemorrhage (0.85 (0.76 to 0.96), P <0.001),
without any increase in thromboembolic complications
[35]. The drug should therefore be considered in all
patients requiring MT. However, it should be noted that
the treatment produced only marginally superior outcomes
compared to the control, and only reached significance due
to the large number of patients studied.Survivor bias
There is a methodological issue with the literature on MT,
as no randomized control trial exists on increased blood
product ratios. Observational studies on transfusion ratios
are prone to survivor bias (SB) as many of the deaths
occur early in the hospital course when administration of
plasma typically lags behind RBCs, and they therefore fall
into the low plasma:RBC ratio group. Conversely patients
surviving long enough to receive sufficient plasma fall into
the high plasma:RBC group. In order to avoid SB some
investigators exclude patients who die within the first hour
or two after arriving at the Emergency Department. Alter-
natively investigators can model the relationship between
mortality and plasma:RBC ratio over time, and treat the
ratio as a time-dependent covariate.
Ho et al. recently reviewed the entirety of the literature
on blood product ratios in trauma to examine the preva-
lence of survivor bias [25]. They reviewed 26 studies on
blood ratios in trauma and found that:
 11 studies that showed a benefit in high plasma:RBC
ratios were SB-prone. This included all four military
studies
 10 studies that showed a benefit in high plasma:RBC
ratios were considered SB-unlikely
 5 other studies were SB-unlikely but showed no
benefit in high plasma:RBC ratios.
Therefore while SB might partly explain the large
reduction in mortality with high plasma:RBC ratios in
some studies, there is still a considerable body of evidence
in favor of early administration of blood products within
a MTP.
Massive transfusion protocols
The improvement in mortality with changes in blood
product ratios has led many hospitals to implement
MTPs [36]. MTPs vary between institutions, but the
principles remain the same. MTP activation is usually
at the discretion of the trauma surgeon or emergency
department physician. Upon activation, blood services
will deliver several ‘rounds’ of blood products containing
RBCs, plasma and platelets to the patient until the protocol
is deactivated.
Riskin and colleagues showed that deaths from trauma
significantly decreased after the introduction of a MTP
[37]. They were already practicing an aggressive transfusion
practice in an attempt to prevent dilutional coagulopathy,
and the survival benefit does not appear to have been
related to any alteration in the volume or ratio of blood
components used. However by allowing expeditious
product availability, the MTP resulted in earlier transfu-
sion of RBCs and a significant decrease in time to first
transfusion of plasma and platelets.
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proved communication and organization within the MTP
enabling earlier delivery of blood products from blood
services. A MTP should enable clinicians to administer 1:1
plasma to RBCs immediately upon admission to hospital,
rather than giving RBCs initially and then plasma at a later
stage. This means that thawed plasma has to be available in
the emergency department for use in the first round of the
MTP instead of having to wait for FFP.
Thawed plasma is simply FFP, which after thawing, is
kept at 4°C for 5 days. Thawed AB plasma is stored in
emergency department refrigerators alongside emergency
release type O blood. This allows both products to be used
immediately and concurrently when a MTP is initiated.
MTPs improve patient survival and also reduce clinician
stress. Another advantage is that MTPs have the potential
for cost savings with earlier control of hemorrhage leading
to decreased overall blood products utilization. O’Keefe
and colleagues reported a saving of $2,270 per patients
after introduction of a MTP [38].
How can we predict who needs a massive transfusion
protocol?
It is extremely important to predict who will need a MT
so that the MTP can be implemented to help prevent
early hemorrhagic deaths. However only 2% of civilian
trauma patients need a MT, so that means that the vast ma-
jority of trauma patients do not need a MTP implemented.
This cannot be overstated as overuse of a MTP can
cause harm as well as leading to wastage in blood bank
products and resources. There is a significant and well-
established risk of TRALI when giving blood components
(predominantly plasma). There is currently no data in
trauma, but in non-trauma studies plasma transfusion was
associated with an almost threefold increased risk of acute
lung injury (ALI) (OR 2.92 (1.99 to 4.29), P = 0.14) [39].
The proposed mechanism of TRALI involves antibodies
from donor blood components that are directed against
Human Leucocyte Antigens (HLA). These antibodies are
most numerous in women who have been pregnant, hence
the risk of TRALI can be reduced by using predominantly
male plasma [40].
It is sometimes difficult to predict who will need a MTP
activated. Dente and colleagues reported an ‘overtriage’
rate of 27% in whom the protocol was activated but the
patient never received a MT [41]. This led them to look
for early clinical markers after torso gunshot wounds
which correlated with the need for MT. They noted that
all patients with transpelvic and mulitcavity gunshot
wounds required MT. Of the patients with isolated
transabdominal or transthoracic bullet trajectories, many
did not require MT. However a systolic pressure less than
90 mmHg and a base deficit of greater than −10 units
were strong predictors of the need for MT.Ultimately a universal set of activation triggers may not
be possible due to practice variations at different trauma
centers, and the final decision will rely on the experience
and judgment of the trauma team.
Point of care coagulation testing
Point of care (POC) coagulation testing is an attractive
alternative to formula-driven approaches to blood transfu-
sion in trauma. POC hemoglobin, prothrombin time, plate-
let count and fibrinogen level and thromboelastography
(TEG™ Haemonetics Corp., Braintree, MA, USA) and
thromboelastometry (ROTEM™, Tem International GmbH,
Munich, Germany) are all available. Currently POC testing
is more commonly used in the majority of trauma patients
who have significant injuries but not enough to activate a
MTP, although as improvements occur in the speed and ac-
curacy of these technologies they may become an alterna-
tive to formula-driven MTPs in the most severe trauma.
Whole-blood viscoelastic tests, such as TEG or ROTEM
provide a real-time graphic representation of clot for-
mation enabling clinicians to individualize correction
of coagulopathy more accurately and substantially
faster than standard coagulation tests [42]. There is in-
creasing evidence that these devices are helpful in guid-
ing coagulation therapy for trauma patients according
to their actual needs. Individualized coagulation man-
agement can potentially reduce the risks or both under-
transfusion and over-transfusion of blood products [43].
However POC coagulation testing is not yet a standard
of care in most hospitals, and studies are needed to
demonstrate improved patient survival or decreased use
of blood products.
Future directions
Several large-scale trials are ongoing that may aid clini-
cians in the management of MT. The US Department of
Defense-sponsored PROMMTT prospective observa-
tional study, which was performed at 10 major U.S.
trauma centers, has recently been completed and will
produce a lot of data on the management of MT in
major centers and outcomes [44].
The first multi-center randomized controlled trial to
compare blood ratios in trauma is being planned in the
United States. The PROPPR (Prospective Randomized
Optimum Platelet and Plasma Ratios) trial will enroll 580
patients in 12 centers over 2 years (ClinicalTrials.gov
Identifier: NCT01545232) Patients will be randomized to
either 1:1:1 or 1:1:2 (platelets:plasma:RBCs),
A formula versus lab-guided study comparing 1:1
versus conventional resuscitation has recently been
completed (ClinicalTrials.gov Identifier: NCT00945542),
and a trial to look at the use of stored whole blood in civilian
trauma is currently in progress. (ClinicalTrials.gov Identifier:
NCT01227005).
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The current available evidence suggests that in severe
trauma with hemorrhagic shock a MTP should be acti-
vated. Patients should be resuscitated with warm fresh
whole blood or best practice component therapy in a
ratio of 1:1:1:1 (plasma:platelets:cryoprecipitate:RBCs).
Tranexamic acid should also be considered. In other
words, if the patient is hemorrhaging whole blood we
should reconstruct whole blood as much as we can.
The benefit of preventing an early hemorrhagic death
far outweighs the risk of subsequent TRALI.
Some authors are advocating a return to the widespread
use of WFWB in major trauma centers [45]. Transfusion
of WFWB has been associated with improved survival
during MT, and also substantially reduces recipient expos-
ure to plasma and platelets, thereby reducing the risk of
TRALI. However, there are major logistical difficulties in
supplying WFWB that would need to be overcome to
overhaul blood services.
Once there is control of surgical bleeding in MT, and
for all patients who did not need a MT point of care co-
agulation tests should be used wherever possible. If there
is no imminent danger of life threatening hemorrhage if
seems prudent to use POC tests to ‘fine tune’ use of blood
products and prevent unnecessary administration.
Conclusions
Reduced crystalloid use upfront, massive transfusion
protocols and 1:1:1 in the absence of whole blood have
all been shown to improve trauma outcomes. There is
growing evidence to suggest that 1:1:1 is the best possible
alternative to fresh blood, together with damage control
resuscitation. However the principles of damage control
resuscitation should only be applied to those patients
who are going to need massive transfusion with life-
threatening hemorrhage.
Once surgical control has been achieved, and in the
98% of patients who do not require a massive transfu-
sion, the ultimate goal would be to individualize blood
product ratios from patient to patient rather than having
a set ratio for all cases. This could be achieved using
point of care coagulation tests, allowing for the delivery
of RBCs, plasma and platelets as and when the patient
needs them.
It is likely that there will be a significant amount of
literature in the near future on the use of lyophilized
plasma and other blood products, which will be of par-
ticular advantage in smaller hospitals and in combat zones
where disease-free blood products will be immediately
available. There may also be an increased drive toward
more widespread use of warm fresh whole blood. Future
clinical trials will define the role of these products and
continue the advances in trauma care that have been
made over the last decade.Abbreviations
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